Seminars in Oncology
Volume 37, Issue 3 , Pages 188-189 , June 2010

The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors Revisited

References 

  1. Chapman P, Cranmer L, Dixon WG, et al. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit?. Semin Oncol. 2010;37:11–19
  2. Leone G. The relationship between immunological defence and the development of tumours. Arch Sci Med (Torino). 1973;130:273–282
  3. Kölsch E, Stumpf R, Weber G. Low zone tolerance and suppressor T cells. Transplant Rev. 1975;26:56–86
  4. Stumpf R, Heuer J, Kölsch E. Suppressor T cells in low zone tolerance (I. Mode of action of suppressor cells). Eur J Immunol. 1977;7:74–85
  5. Heuer J, Stumpf R, Kölsch E, Shen FW, Hämmerling GJ. Suppressor T cells in low zone tolerance (II. Characterization of suppressor T and amplifier cells by physical and serological methods). Eur J Immunol. 1977;7:769–775
  6. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist. 2008;13(Suppl 4):10–15
  7. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204–1210
  8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszweski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. Aids. 1997;11:1731–1738
  9. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728–736
  10. Mitsuyasu RT. Non–AIDS-defining malignancies in HIV. Top HIV Med. 2008;16:117–121
  11. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep. 1978;62:1117–1133

 Address correspondence to Gloria J. Morris, MD, PhD, Editor, Current Clinical Practice, Hematology and Oncology Associates of Northeastern PA, PC, 1100 Meade St, Dunmore, PA 18512. E-mail: dr.morris@hemonc1.com

PII: S0093-7754(10)00089-8

doi: 10.1053/j.seminoncol.2010.06.010

Seminars in Oncology
Volume 37, Issue 3 , Pages 188-189 , June 2010

Article Tools